CARsgen Therapeutics Holdings Ltd., a company specializing in innovative CAR T-cell therapies, has announced significant regulatory advancements for its product satricabtagene autoleucel, known as "satri-cel." The Center for Drug Evaluation $(CDE)$ of China's National Medical Products Administration (NMPA) has granted satri-cel Breakthrough Therapy Designation and Priority Review for treating Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma in patients who have failed at least two previous lines of therapy. CARsgen is set to submit a New Drug Application (NDA) to the NMPA this month, with anticipation of approval as the first commercially available CAR-T product for solid tumors globally. This development marks a major milestone in the field, offering new hope for patients with limited treatment options.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.